financetom
Business
financetom
/
Business
/
Textbook publisher McGraw Hill targets $4.2 billion valuation in US IPO
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Textbook publisher McGraw Hill targets $4.2 billion valuation in US IPO
Jul 14, 2025 3:55 AM

(Reuters) -U.S. publisher McGraw Hill is targeting a valuation of $4.2 billion in its IPO, the company said on Monday, adding to a recent line up of public market hopefuls that are looking to tap an improvement in investor sentiment.

Activity in the U.S. IPO market has seen an uplift in recent months as the trade policy confusion settles with investors flocking to new listings of companies like stablecoin issuer Circle Internet Group ( CRCL ) and Chime Financial ( CHYM ).

Columbus, Ohio-based McGraw Hill is looking to raise up to $537 million from 24.39 million shares priced between $19 and $22 apiece.

McGraw Hill is one of the most recognized names in the publishing industry, and has a global sales team of nearly 1,500.

The company will aim to trade on the NYSE under the symbol "MH". Goldman Sachs is the lead underwriter for the IPO.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Concentra Acquires Assets of Physicians Health Center, OM Management
Concentra Acquires Assets of Physicians Health Center, OM Management
Mar 10, 2025
09:09 AM EDT, 03/10/2025 (MT Newswires) -- Concentra Group (CON) said Monday it has acquired the assets of Physicians Health Center and OM Management. Financial terms weren't disclosed. The occupational health services provider will offer work injury care, physical therapy, drug testing, DOT physical exams, pre-placement exams, and other employer-related health services from its new physicians health center locations in...
Arrowhead Pharmaceuticals Says Study for Complement-Mediated Disease Therapy Shows C3 Reduction in Patients
Arrowhead Pharmaceuticals Says Study for Complement-Mediated Disease Therapy Shows C3 Reduction in Patients
Mar 10, 2025
09:12 AM EDT, 03/10/2025 (MT Newswires) -- Arrowhead Pharmaceuticals ( ARWR ) said Monday that topline results of the clinical study of its investigational RNA interference therapeutic ARO-C3 showed an 89% mean reduction in complement component 3, supporting it as a potential therapy for various complement-mediated diseases. The second part of the phase 1/2 clinical study also showed reductions of...
Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity
Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity
Mar 10, 2025
On Monday, Beam Therapeutics Inc. ( BEAM ) announced initial safety and efficacy data from its Phase 1/2 trial of BEAM-302, establishing clinical proof-of-concept as a potential treatment for alpha-1 antitrypsin deficiency (AATD) and for in vivo base editing. The initial safety and efficacy data reported are from all nine patients as of February 26, the data cut-off date. Preliminary results from the first...
Spin Master Renews Global Master Toy Partner Agreement with Universal Products & Experiences
Spin Master Renews Global Master Toy Partner Agreement with Universal Products & Experiences
Mar 10, 2025
09:05 AM EDT, 03/10/2025 (MT Newswires) -- Spin Master ( SNMSF ) on Monday renewed its global master toy licensee agreement with Universal Products & Experiences for DreamWorks Animation's popular preschool brand Gabby's Dollhouse. The company is preparing a new toy line which will launch in the fall, inspired by DreamWorks Animation's upcoming feature film, Gabby's Dollhouse: The Movie. Shares...
Copyright 2023-2026 - www.financetom.com All Rights Reserved